Improvement in 3 Noninvasive Tests Through 144 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta With and Without Virologic Response

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
May 7-10, 2025
Amsterdam the Netherlands


Improvement in 3 Noninvasive Tests Through 144 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta With and Without Virologic Response

	EASL 2025 May 7-10 Amsterdam